uploads/2018/02/medical-pic-U4FyCp3-KzY.jpg

Boston Scientific: Analysts’ Ratings in February 2018

By

Updated

Boston Scientific

Boston Scientific (BSX) is a medical company with a global presence. Boston Scientific focuses on developing, manufacturing, and marketing a wide range of interventional medical specialties. The company has grown through strategic acquisitions. The acquisitions helped Boston Scientific expand its product portfolio in the core areas of cardiovascular, rhythm management, and medical surgery.

Article continues below advertisement

Analysts’ recommendations

In February 2018, 21 of the 26 analysts covering Boston Scientific gave it a “buy” or higher rating, while five analysts gave it a “hold” rating. The mean rating for the stock is 1.85 with a target price of $27.55.

Peers’ ratings

Of the 21 analysts covering Abbott Laboratories (ABT) in February 2018, seven analysts gave the stock a “strong buy” rating, ten analysts gave it a “buy” rating, and four analysts gave it a “hold” rating. The mean rating for the stock is 1.86 with a target price of $68.2.

Of the 23 analysts covering Johnson & Johnson (JNJ) in February 2018, 12 analysts gave the stock a “buy” or higher rating, eight analysts gave it a “hold” rating, and three analysts gave it a “sell” or lower rating. The mean rating for the stock is 2.43 with a target price of $150.6.

Of the 24 analysts covering Medtronic (MDT) in February 2018, six analysts gave the stock a “strong buy” rating, eight analysts gave it a “buy” rating, and ten analysts gave it a “hold” rating. The mean rating for the stock is 2.17 with a target price of $91.4.

Next, we’ll analyze Boston Scientific’s business strategy.

Advertisement

More From Market Realist